目的 分析儿童肛周瘘管型克罗恩病（perianal fistulizing Crohn's disease, pfCD）患儿的临床特征、治疗及预后。 方法 回顾性选择2015年4月—2023年4月间诊断为克罗恩病（Crohn's disease, CD）的6~17岁患儿142例为研究对象，根据是否存在肛周瘘管型病变，分为pfCD组（60例）和非pfCD组（82例），比较两组患儿的临床特征、治疗及预后。 结果 pfCD发生率为42.3%（60/142）。pfCD组男性比例，病变范围累及结肠、小肠结肠比例，以及合并上消化道病变的比例高于非pfCD组（P<0.05）。pfCD组英夫利西单抗诱导缓解及维持缓解治疗比例高于非pfCD组（P<0.05）。pfCD组中，复杂性肛瘘患儿占62%（37/60），肛瘘非切割性挂线引流术治疗在复杂性肛瘘患儿中比例为62%（23/37），显著高于简单性肛瘘患儿（4%，1/23）（P<0.05）。两组患儿治疗54周黏膜愈合率和临床缓解率差异均无统计学意义（P>0.05）。pfCD组治疗54周瘘管愈合率为57%（34/60），其中简单性肛瘘患儿瘘管愈合率高于复杂性肛瘘患儿（P<0.05）。 结论 儿童CD患者中pfCD发生率高，pfCD患儿生物制剂使用比例高，复杂性肛瘘非切割性挂线引流术比例高，CD患儿随访中需要密切关注pfCD的发生。
Abstract
Objective To investigate the clinical characteristics, treatment, and prognosis of children with perianal fistulizing Crohn's disease (pfCD). Methods A retrospective analysis was conducted on the children, aged 6-17 years, who were diagnosed with Crohn's disease (CD) from April 2015 to April 2023. According to the presence or absence of perianal fistulizing lesions, they were divided into two groups: pfCD (n=60) and non-pfCD (n=82). The two groups were compared in terms of clinical characteristics, treatment, and prognosis. Results The incidence of pfCD was 42.3% (60/142). The proportion of males in the pfCD group was higher than that in the non-pfCD group. Compared with the non-pfCD group, the pfCD group had a significantly higher proportion of children with involvement of the colon and small intestine or those with upper gastrointestinal lesions (P<0.05). Compared with the non-pfCD group, the pfCD group had a significantly higher rate of use of infliximab during both induction and maintenance treatment (P<0.05). In the pfCD group, the children with complex anal fistula accounted for 62% (37/60), among whom the children receiving non-cutting suspended line drainage accounted for 62% (23/37), which was significantly higher than the proportion among the children with simple anal fistula patients (4%, 1/23) (P<0.05). There were no significant differences between the two groups in mucosal healing rate and clinical remission rate at week 54 of treatment (P>0.05). The pfCD group achieved a fistula healing rate of 57% (34/60) at week 54, and the children with simple anal fistula had a significantly higher rate than those with complex anal fistula (P<0.05). Conclusions There is a high incidence rate of pfCD in children with CD, and among the children with pfCD, there is a high proportion of children with the use of biological agents. There is a high proportion of children receiving non-cutting suspended line drainage among the children with complex anal fistula. The occurrence of pfCD should be closely monitored during the follow-up in children with CD.
关键词
克罗恩病 /
肛周瘘管型克罗恩病 /
临床特征 /
治疗 /
儿童
Key words
Crohn's disease /
Perianal fistulizing Crohn's disease /
Clinical characteristic /
Treatment /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review[J]. J Clin Gastroenterol, 2012, 46(7): 581-589. PMID: 22772738. PMCID: PMC3972042. DOI: 10.1097/MCG.0b013e318247c32f.
2 Tarrant KM, Barclay ML, Frampton CM, et al. Perianal disease predicts changes in Crohn's disease phenotype: results of a population-based study of inflammatory bowel disease phenotype[J]. Am J Gastroenterol, 2008, 103(12): 3082-3093. PMID: 19086959. DOI: 10.1111/j.1572-0241.2008.02212.x.
3 Herman Y, Rinawi F, Rothschild B, et al. The characteristics and long-term outcomes of pediatric Crohn's disease patients with perianal disease[J]. Inflamm Bowel Dis, 2017, 23(9): 1659-1665. PMID: 28590344. DOI: 10.1097/MIB.0000000000001171.
4 Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease[J]. Inflamm Bowel Dis, 2009, 15(3): 383-387. PMID: 19023863. DOI: 10.1002/ibd.20767.
5 Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease[J]. J Crohns Colitis, 2014, 8(10): 1179-1207. PMID: 24909831. DOI: 10.1016/j.crohns.2014.04.005.
6 中华医学会儿科学分会消化学组, 中华医学会儿科学分会临床营养学组. 儿童炎症性肠病诊断和治疗专家共识[J]. 中华儿科杂志, 2019, 57(7): 501-507. PMID: 31269548. DOI: 10.3760/cma.j.issn.0578‐1310.2019.07.002.
7 Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index[J]. J Pediatr Gastroenterol Nutr, 1991, 12(4): 439-447. PMID: 1678008.
8 Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)[J]. Gut, 1989, 30(7): 983-989. PMID: 2668130. PMCID: PMC1434265. DOI: 10.1136/gut.30.7.983.
9 Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties[J]. Am J Gastroenterol, 2010, 105(9): 2085-2092. PMID: 20372111. DOI: 10.1038/ajg.2010.143.
10 Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings[J]. Inflamm Bowel Dis, 2008, 14(1): 40-46. PMID: 18022866. DOI: 10.1002/ibd.20312.
11 Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification[J]. Inflamm Bowel Dis, 2011, 17(6): 1314-1321. PMID: 21560194. DOI: 10.1002/ibd.21493.
12 Sandborn WJ, Fazio VW, Feagan BG, et al. Aga technical review on perianal Crohn's disease[J]. Gastroenterology, 2003, 125(5): 1508-1530. PMID: 14598268. DOI: 10.1016/j.gastro.2003.08.025.
13 Adler J, Dong S, Eder SJ, et al. Perianal crohn disease in a large multicenter pediatric collaborative[J]. J Pediatr Gastroenterol Nutr, 2017, 64(5): e117-e124. PMID: 27801750. DOI: 10.1097/MPG.0000000000001447.
14 Eglinton TW, Roberts R, Pearson J, et al. Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort[J]. Am J Gastroenterol, 2012, 107(4): 589-596. PMID: 22158027. DOI: 10.1038/ajg.2011.437.
15 克罗恩病肛瘘共识专家组. 克罗恩病肛瘘诊断与治疗的专家共识意见[J]. 中华炎性肠病杂志, 2019, 3(2): 105-110. DOI: 10.3760/cma.j.issn.2096-367X.2019.02.001.
16 Laland M, Fran?ois M, D'Amico F, et al. Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn's disease[J]. Colorectal Dis, 2023, 25(1): 75-82. PMID: 36016511. DOI: 10.1111/codi.16314.
17 Singh A, Midha V, Kochhar GS, et al. Management of perianal fistulizing Crohn's disease[J]. Inflamm Bowel Dis, 2023. Epub ahead of print. PMID: 37672347. DOI: 10.1093/ibd/izad195.
18 Jeon M, Song K, Koo J, et al. Evaluation of a seton procedure combined with infliximab therapy (early vs. late) in perianal fistula with crohn disease[J]. Ann Coloproctol, 2019, 35(5): 249-253. PMID: 31726000. PMCID: PMC6863002. DOI: 10.3393/ac.2018.11.23.1.
19 de Groof EJ, Sahami S, Lucas C, et al. Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment[J]. Colorectal Dis, 2016, 18(7): 667-675. PMID: 26921847. DOI: 10.1111/codi.13311.
PDF(570 KB)
